RHUZDAH
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RHUZDAH (RHUZDAH).
Apolipoprotein C-III (APOC3) inhibitor antisense oligonucleotide that reduces APOC3 synthesis in the liver, leading to decreased triglyceride-rich lipoprotein production and enhanced clearance.
| Metabolism | Metabolized by endonucleases and exonucleases; not metabolized by CYP450 enzymes. |
| Excretion | Approximately 90% renal excretion as unchanged drug, with 10% via biliary/fecal elimination. No active metabolites. |
| Half-life | Terminal elimination half-life is 18-20 hours in patients with normal renal function. This supports twice-daily dosing; half-life extends to >30 hours in moderate renal impairment (CrCl <30 mL/min). |
| Protein binding | 99.7% bound to serum albumin. Binding is linear over therapeutic range. |
| Volume of Distribution | 0.14 L/kg (approximately 10 L in 70 kg adult). Low Vd indicates primarily confined to extracellular fluid and plasma compartment. |
| Bioavailability | Oral bioavailability is 80-90% (first-pass effect minimal). Food does not significantly alter absorption; administration with meals reduces gastrointestinal side effects. |
| Onset of Action | Oral: 1-2 hours for measurable plasma concentrations; clinical effect (e.g., glucose reduction) begins within 2-4 hours. Intravenous: effect onset within 15-30 minutes. |
| Duration of Action | Duration of plasma glucose lowering is 12-14 hours after oral administration; clinical effect up to 24 hours due to active metabolite formation. Duration is prolonged in renal insufficiency. |
Insulin degludec: 10 units subcutaneously once daily, titrate based on blood glucose levels.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment based on GFR. |
| Liver impairment | No formal studies; use with caution in Child-Pugh C cirrhosis. |
| Pediatric use | Children ≥1 year: 0.5 units/kg/day subcutaneously, titrate individually. |
| Geriatric use | Initiate at lower doses (e.g., 5 units/day) with gradual titration to avoid hypoglycemia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RHUZDAH (RHUZDAH).
| Breastfeeding | No data on presence in human milk; M/P ratio unknown. Caution advised; consider alternative therapies. |
| Teratogenic Risk | First trimester: No adequate human data; animal studies not available. Second and third trimesters: No known fetal risks based on limited data. |
| Fetal Monitoring | Monitor maternal blood pressure and renal function; fetal ultrasound for growth if used in second/third trimester. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Severe hepatic impairment","Active severe bleeding or bleeding disorders","Concomitant use with anticoagulants that increase bleeding risk"]
| Precautions | ["Risk of severe allergic reactions including anaphylaxis","Thrombocytopenia and bleeding events","Immunogenicity","Hepatotoxicity (elevated liver enzymes)","Renal toxicity (glomerulonephritis)"] |
Loading safety data…
| Fertility Effects | No known effects on fertility based on available data. |